The InhiBETTM Platform: Bromodomain and End Terminal (BET) Inhibitors in Autoimmune Disease
Time: 11:00 am
day: Day One
- Review BET protein antagonism and MoA in autoimmune disease, what have we learned?
- Explore drug design and disposition strategies to optimize benefit/risk of BET inhibitors
- Introducing VYN201, a highly potent BD1/BD2 BET protein inhibitor, for locallyacting treatment of major immuno-inflammatory